Expert Review of Vaccines

Article	Citations
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada	93
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy	85
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?	69
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States	61
Indirect protection from rotavirus vaccines: a systematic review	55
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study	54
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response	53
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic	48
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children	45
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions	45
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays	44
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom	43
Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008–2024	40
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China	40
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review	37
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus	37
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection	33
Microarray patches: scratching the surface of vaccine delivery	31
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis	30
Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms	30
The important lessons lurking in the history of meningococcal epidemiology	29
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era	28
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China	27
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy	26
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond	26

Addressing RSV infection in older adults: implications for public health policy	26
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany	26
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada	26
Birth order and influenza vaccination: a comparative study of behaviors and intentions between first-time and second-time Chinese parents	25
Vaccine hesitancy among 0–6-year-olds’ guardians in Chongqing: a cross-sectional survey revealing how immunization program managers’ robust comprehensive capacity for adverse events following immuniza	25
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan	24
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment	24
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above	24
Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America	24
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative	24
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion	24
Adult respiratory syncytial virus infection and community-acquired pneumonia: pathogenesis, diagnostic challenges and the clinical implications	24
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis	23
Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years	23
From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus	23
Cost-effectiveness of cell-based influenza vaccine in France	23
Vaccines preventing neonatal sepsis: focus on Group B Streptococcus , Klebsiella pneumoniae and	23
Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023–24 in six European countries: a VEBIS-EHR network study	22
TAK-003: development of a tetravalent dengue vaccine	22
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination	21
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany	21
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru	21
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China	21
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia	21
Reply to: Letter to Editor “Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine”	21
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic	20
Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics	20
Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development	20
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population	20
Travelers’ preferences for tick-borne encephalitis vaccination	19
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China	19
Vaccines against mpox: MVA-BN and LC16m8	19
Adjuvant system AS01: from mode of action to effective vaccines	19
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems	19
Anti-neuraminidase immunity in the combat against influenza	19
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children	18
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o	18
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease	18
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination	18
The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study	18
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect	18
Vaccination policies for dentists and other dental professionals in Europe: a systematic report	17
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines	17
Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges	17
Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness	17
The durability of vaccine-induced protection: an overview	17
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States	17
Suspended cell lines for inactivated virus vaccine production	17
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–2019	16
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks	16

Estimating the time required to reach HPV vaccination targets across Europe	15
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?	15
Impact of rotavirus vaccination on diarrheal disease burden of children in South America	15
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review	15
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan	15
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine	14
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis	14
Public health impact and return on investment of the pediatric immunization program in Poland	14
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study	14
Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review	14
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs	14
Pneumococcal conjugate vaccines in older adults and immunocompromised individuals	14
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study	14
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome	14
Have mRNA vaccines sentenced DNA vaccines to death?	13
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era	13
Health behaviors are largely not predictive of adverse events following influenza vaccination	13
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations	13
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza	13
Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023/24 season in Spain	13
COVID-19 and vaccination: myths vs science	13
Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model	13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice	13
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses	13
Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit–cost analysis	13
Correction	13
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older	13
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions	12
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella	12
Vaccines against SARS-CoV-2 variants and future pandemics	12
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients	12
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution	12
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines	12
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis	12
Subolesin: a 20-year path from discovery to an effective tick vaccine	12
Approaches to observational study designs and analytical options to evaluate the safety of multi-dose vaccines: a systematic review	11
Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan	11
Correction	11
Vaccine clinical trials in low- and middle-income countries: a brief review of standard, newer and proposed approaches	11
An overview: CRISPR/Cas-based gene editing for viral vaccine development	11
Assessment of the comprehensiveness of paediatric national immunisation programmes in Europe: expert validation and future perspectives	11
A human Lyme disease vaccine: two steps forward on the path to prevention	11
An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants	11
Emergence of mRNA vaccines in the management of cancer	10
Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018–2024: a database study	10
Understanding barriers to vaccination against invasive meningococcal disease: a survey of the knowledge gap and potential solutions	10
Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States	10
Time lapses between distribution of influenza vaccines to health authorities and their administration by General Practitioners (GPs) to older adults: a retrospective study over five influenza seasons	10
A retrospective cohort study: vaccination status and safety analysis of SARS-CoV-2 vaccine in patients with Wilson’s disease	10
Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context	10
Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore	10
Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data	10
Letter to the editor in response to: A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children	10
Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen	10
COVID-19 vaccine design and vaccination strategy for emerging variants	9
Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy	9
Application of reverse cumulative distribution curve and scaled logit model in determining optimal immunogenic dose and prediction of protection of EV71 vaccines	9
Evaluation of varicella outbreak control following implementation of a two-dose free vaccination policy in Wuxi, China (2014–2024)	9
Pneumococcal vaccination willingness and influencing factors among older adults in Chongqing, China: a cross-sectional study based on the WHO’s behavioral and social drivers of vaccination framework	9
Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness	9
Modeling the potential public health and economic impact of different COVID-19 vaccination strategies with an adapted vaccine in the Kingdom of Saudi Arabia	9
Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand	9
Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies	9
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant	9
The role of bactericidal and opsonic activity in immunity against Bordetella pertussis	9
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis	8
Cost-effectiveness of nonavalent HPV vaccination in the Netherlands	8
Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case–control study	8
Epidemiological characteristics of varicella and factors associated with breakthrough varicella among children aged 0–14 years in Jiangsu Province, China	8
A review of data systems for assessing the impact of HPV vaccination in selected high-income countries	8
Tackling vaccine inequity in 2023: have we made progress?	8
Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan	8
Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data	8
Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants	8
Herpes zoster vaccine awareness and determinants among chinese adults aged ≥ 60 years: a cross-sectional study	8
Research progress on immune mechanism and control strategy of dsRNA impurities in mRNA vaccine	8
Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule	7
Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity	7
Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin American countries	7
Antigenic drift in SARS-CoV-2: diminished vaccine protection in pediatric populations against Omicron and its JN.1 subvariant	7

No observable influence of COVID-19 inactivated vaccines on pregnancy and birth outcomes in the first trimester of gestation	7
Risk of herpes zoster following mRNA COVID-19 vaccine administration	7
Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses	7
Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies	7
Adult vaccination against respiratory infections in Egypt: a review of expert opinions	7
Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study	7
Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study	7
Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs	7
Respiratory syncytial virus infection and the need for immunization in Korea	7
Recent advances in the development of a vaccine to target meningococcal serogroup X	7
Measuring psychosocial determinants of vaccination behavior in healthcare professionals: validation of the Pro-VC-Be short-form questionnaire	7
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial	7
A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China	7
Healthcare providers’ preferences for pediatric pneumococcal vaccination recommendations in the United States	7
Global variations in immunisation strategies against pertussis in infancy	6
Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers	6
Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate	6
Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward	6
The use of electroporation to deliver DNA-based vaccines	6
Interrupted time-series analysis of nationwide surveillance in Thai adult pneumococcal diseases over 14 years: evidence to inform policy in resource-limited countries	6
Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India	6
Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar	6
The quest for an HIV-1 vaccine: will mRNA deliver us from evil?	6
Developing a global framework to assess a country’s readiness and resilience to introduce a new vaccine or improve uptake of an underutilized vaccine	6
The zebrafish as a potential model for vaccine and adjuvant development	6
Contextual adaptation and validation of the international Pro-VC-Be tool for measuring healthcare worker vaccine confidence in Nigeria	6
Vaccination against pertussis in Latin American preterm and low-birth weight infants: experts opinion position for a neglected childhood age group	6
Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults	6
Combatting infectious diarrhea: innovations in treatment and vaccination strategies	6
The broader benefits of vaccines: methodologies for inclusion in economic evaluation	6
The broader socio-economic value of adult respiratory disease vaccinations in the UK – results from a benefit cost analysis	6
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study	6
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis	6
Beyond aggregate estimates: stratified self-controlled case series analyses and insights into COVID-19 vaccine safety	6
Control measures for neglected tropical diseases: vaccine updates	6
Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review	6
Protection and waning of vaccine-induced, natural and hybrid immunity to SARS-CoV-2 in Hong Kong	5
Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies	5
Toward elimination of hepatitis A and B in Europe: vaccination successes, challenges, and opportunities	5
Typhoid conjugate vaccines: is a single dose enough for durable protection?	5
Immune mechanisms targeting malaria transmission: opportunities for vaccine development	5
Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children	5
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines	5
Novel approaches to reactivate pertussis immunity	5
An analysis of causality assessed serious and severe adverse events following COVID-19 vaccines administered from January 2021 to September 2022 in India	5
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity	5
When precision medicine meets rigid vaccination: bridging the policy gap for patients on biologics	5
A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia	5
Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England	5
COVID-19 vaccines: the start of a new era in regulation?	5
Eliminating nonmedical exemptions: a radical shift in how childhood vaccine mandates govern	5
Further implications on the global real-world vaccine effectiveness against SARS-CoV-2	4
The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development	4
Vaccine development for pathogenic fungi: current status and future directions	4
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using a COVID-19 vaccine in Costa Rica	4
Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary	4
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine	4
Challenges in vaccine transport: can we deliver without the cold chain?	4
Correction	4
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial	4
Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis	4
PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children	4
Controlling the COVID-19 pandemic through vaccination: a perspective from Indonesia	4
Suboptimal vaccine uptake and vaccine hesitancy in the United States: current challenges and future directions	4
Hookworm vaccines: current and future directions	4
A policy review of the introduction of the MenACWY vaccine in toddlers across multiple countries	4
Patterns of co-administration and sequential administration of COVID-19 and influenza vaccinations: a US study using Adheris pharmacy dataset	4
Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infa	4
Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus	4
Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany	4
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells	4
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine	4
Whole cell and acellular pertussis vaccines - rethinking the evidence	4
A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza	4
Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance	4
Risks of low vaccination coverage and strategies to prevent the resurgence of vaccine-preventable diseases in infants in the COVID-19 pandemic scenario: recommendations for Latin America and the Carib	4
Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review	4
Chlamydia trachomatisvaccine development – a view on the current challenges and how to move forward	4
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews	4
Immunization information systems’ implementation and characteristics across the world: a systematic review of the literature	4